糖尿病用非インスリン治療薬のグローバル市場2023~2027:DPP4阻害剤、GLP-1受容体アゴニスト、SGLT2阻害剤、その他

【英語タイトル】Global Non-insulin Diabetes Therapeutics Market 2023-2027

Technavioが出版した調査資料(IRTNTR70604-23)・商品コード:IRTNTR70604-23
・発行会社(調査会社):Technavio
・発行日:2023年5月4日
・ページ数:約120
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:北米、ヨーロッパ、アジア太平洋、アメリカ、ドイツ、中国、イギリス、インド、その他地域
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥380,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥608,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Technavio社の本市場調査レポートでは、世界の糖尿病用非インスリン治療薬市場規模が2022年から2027年の間に31,251.55百万ドルまで到達し、予測期間中に年平均10.82%成長すると見込まれます。本レポートでは糖尿病用非インスリン治療薬の世界市場について多角的に調査・分析し、エグゼクティブサマリー、市場状況、市場規模予測、過去の市場規模、ファイブフォース分析、種類別(DPP4阻害剤、GLP-1受容体アゴニスト、SGLT2阻害剤、その他)分析、流通チャネル別(オフライン、オンライン)分析、地域別状況(北米、ヨーロッパ、アジア太平洋、アメリカ、ドイツ、中国、イギリス、インド、その他)分析、成長要因・課題・動向、企業状況、企業分析などの内容を掲載しています。なお、参入企業情報としてAbbott Laboratories、AstraZeneca PLC、Better Therapeutics Inc.、Boehringer Ingelheim International GmbH、Eli Lilly and Co.、F. Hoffmann La Roche Ltd.、GlaxoSmithKline Plc、Johnson and Johnson Services Inc.、Merck KGaA、Novartis AG、Novo Nordisk AS、Pfizer Inc.などが含まれています。
・市場状況
・市場規模予測
・過去の市場規模
・ファイブフォース分析
・世界の糖尿病用非インスリン治療薬市場規模:種類別
- DPP4阻害剤の市場規模
- GLP-1 受容体アゴニストの市場規模
- SGLT2阻害剤の市場規模
- その他種類の市場規模
・世界の糖尿病用非インスリン治療薬市場規模:流通チャネル別
- オフラインチャネルの市場規模
- オンラインチャネルの市場規模
・地域別状況
- 北米の糖尿病用非インスリン治療薬市場規模
- ヨーロッパの糖尿病用非インスリン治療薬市場規模
- アジア太平洋の糖尿病用非インスリン治療薬市場規模
- その他地域の糖尿病用非インスリン治療薬市場規模
- アメリカの糖尿病用非インスリン治療薬市場規模
- ドイツの糖尿病用非インスリン治療薬市場規模
- 中国の糖尿病用非インスリン治療薬市場規模
- イギリスの糖尿病用非インスリン治療薬市場規模
- インドの糖尿病用非インスリン治療薬市場規模
・成長要因・課題・動向
・企業状況
・企業分析

Technavio社は、利益、価格、競争、プロモーションなどの主要な変数を分析することで、また、複数のソースからのデータを調査・統合・合計することにより、糖尿病用非インスリン治療薬市場の詳細な全体像を提示します。主要産業のインフルエンサーを特定することで、さまざまな市場の側面を提示します。提示されたデータは包括的​​で信頼性が高く、一次および二次の広範な調査の結果です。Technavio社の市場調査レポートは、正確な糖尿病用非インスリン治療薬市場の成長を予測するための定性的・定量的調査を用い、徹底的な競合状況と詳細に及ぶベンダー選定・分析を提供します。

糖尿病用非インスリン治療薬の世界市場 2023-2027

糖尿病用非インスリン治療薬市場は、2022年から2027年にかけて3億1,251.55万米ドルの成長が予測され、予測期間中のCAGRは10.82%で加速すると予測されます。この調査レポートは、糖尿病用非インスリン治療薬市場の全体的な分析、市場規模と予測、動向、成長促進要因、課題を掲載し、約25のベンダーを網羅したベンダー分析も掲載しています。
当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。2型糖尿病患者の増加、6~19歳および35~50歳の糖尿病有病率の増加、最近の製品承認などが市場を牽引しています。

Technavio社の糖尿病用非インスリン治療薬市場は以下のように区分されます:

・タイプ別:
– DPP4阻害薬
– GLP-1受容体作動薬
– SGLT2阻害薬
– その他

・販売チャネル別:
– オフライン
– オンライン

・地域別:
– 北米
– ヨーロッパ
– アジア
– その他の地域(ROW)

本調査では、今後数年間における糖尿病用非インスリン治療薬市場の成長を促進する主な要因の一つとして、治療法の革新を挙げています。また、ベンダー間の戦略的提携や併用薬に対する需要の増加は、市場の大きな需要につながるでしょう。

この調査レポートは、糖尿病用非インスリン治療薬市場を調査・分析し、以下の刊行物を出版しています:
– 糖尿病用非インスリン治療薬市場のサイジング
– 糖尿病用非インスリン治療薬市場予測
– 糖尿病用非インスリン治療薬市場の産業分析

強固なベンダー分析は、クライアントが市場でのポジションを向上できるように設計されており、これに沿って本レポートには、Abbott Laboratories, AstraZeneca PLC, Better Therapeutics Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and The Cleveland Clinic Foundationなどの企業情報が含まれています。また、糖尿病用非インスリン治療薬市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。当レポートでは、主要ベンダーの分析に加え、包括的な市場とベンダーの状況を掲載しています。

当出版社は、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、要約することによって、市場の詳細な姿を提示します。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示しています。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global non-insulin diabetes therapeutics market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on global non-insulin diabetes therapeutics market 2017 – 2021 ($ million)
o 4.2 Type Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Type Segment 2017 – 2021 ($ million)
o 4.3 Distribution Channel Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Distribution Channel Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Type
o 6.1 Market segments
o Exhibit 30: Chart on Type – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Type – Market share 2022-2027 (%)
o 6.2 Comparison by Type
o Exhibit 32: Chart on Comparison by Type
o Exhibit 33: Data Table on Comparison by Type
o 6.3 DPP4 inhibitors – Market size and forecast 2022-2027
o Exhibit 34: Chart on DPP4 inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on DPP4 inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on DPP4 inhibitors – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on DPP4 inhibitors – Year-over-year growth 2022-2027 (%)
o 6.4 GLP-1 receptor agonists – Market size and forecast 2022-2027
o Exhibit 38: Chart on GLP-1 receptor agonists – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on GLP-1 receptor agonists – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on GLP-1 receptor agonists – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on GLP-1 receptor agonists – Year-over-year growth 2022-2027 (%)
o 6.5 SGLT2 inhibitors – Market size and forecast 2022-2027
o Exhibit 42: Chart on SGLT2 inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 43: Data Table on SGLT2 inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 44: Chart on SGLT2 inhibitors – Year-over-year growth 2022-2027 (%)
o Exhibit 45: Data Table on SGLT2 inhibitors – Year-over-year growth 2022-2027 (%)
o 6.6 Others – Market size and forecast 2022-2027
o Exhibit 46: Chart on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 47: Data Table on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 48: Chart on Others – Year-over-year growth 2022-2027 (%)
o Exhibit 49: Data Table on Others – Year-over-year growth 2022-2027 (%)
o 6.7 Market opportunity by Type
o Exhibit 50: Market opportunity by Type ($ million)
o Exhibit 51: Data Table on Market opportunity by Type ($ million)
• 7 Market Segmentation by Distribution Channel
o 7.1 Market segments
o Exhibit 52: Chart on Distribution Channel – Market share 2022-2027 (%)
o Exhibit 53: Data Table on Distribution Channel – Market share 2022-2027 (%)
o 7.2 Comparison by Distribution Channel
o Exhibit 54: Chart on Comparison by Distribution Channel
o Exhibit 55: Data Table on Comparison by Distribution Channel
o 7.3 Offline – Market size and forecast 2022-2027
o Exhibit 56: Chart on Offline – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Data Table on Offline – Market size and forecast 2022-2027 ($ million)
o Exhibit 58: Chart on Offline – Year-over-year growth 2022-2027 (%)
o Exhibit 59: Data Table on Offline – Year-over-year growth 2022-2027 (%)
o 7.4 Online – Market size and forecast 2022-2027
o Exhibit 60: Chart on Online – Market size and forecast 2022-2027 ($ million)
o Exhibit 61: Data Table on Online – Market size and forecast 2022-2027 ($ million)
o Exhibit 62: Chart on Online – Year-over-year growth 2022-2027 (%)
o Exhibit 63: Data Table on Online – Year-over-year growth 2022-2027 (%)
o 7.5 Market opportunity by Distribution Channel
o Exhibit 64: Market opportunity by Distribution Channel ($ million)
o Exhibit 65: Data Table on Market opportunity by Distribution Channel ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 67: Chart on Market share By Geographical Landscape 2022-2027 (%)
o Exhibit 68: Data Table on Market share By Geographical Landscape 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 69: Chart on Geographic comparison
o Exhibit 70: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 71: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 72: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 73: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 74: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 75: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 76: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 77: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 78: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 79: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 80: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 81: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 82: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 83: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 84: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 85: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 86: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 87: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 88: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 89: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 90: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 Germany – Market size and forecast 2022-2027
o Exhibit 91: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 92: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 93: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 94: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.9 China – Market size and forecast 2022-2027
o Exhibit 95: Chart on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 96: Data Table on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 97: Chart on China – Year-over-year growth 2022-2027 (%)
o Exhibit 98: Data Table on China – Year-over-year growth 2022-2027 (%)
o 9.10 UK – Market size and forecast 2022-2027
o Exhibit 99: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 100: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 101: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 102: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.11 India – Market size and forecast 2022-2027
o Exhibit 103: Chart on India – Market size and forecast 2022-2027 ($ million)
o Exhibit 104: Data Table on India – Market size and forecast 2022-2027 ($ million)
o Exhibit 105: Chart on India – Year-over-year growth 2022-2027 (%)
o Exhibit 106: Data Table on India – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 107: Market opportunity By Geographical Landscape ($ million)
o Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 109: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 111: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 112: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 113: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 114: Matrix on vendor position and classification
o 12.3 Abbott Laboratories
o Exhibit 115: Abbott Laboratories – Overview
o Exhibit 116: Abbott Laboratories – Business segments
o Exhibit 117: Abbott Laboratories – Key news
o Exhibit 118: Abbott Laboratories – Key offerings
o Exhibit 119: Abbott Laboratories – Segment focus
o 12.4 AstraZeneca PLC
o Exhibit 120: AstraZeneca PLC – Overview
o Exhibit 121: AstraZeneca PLC – Product / Service
o Exhibit 122: AstraZeneca PLC – Key news
o Exhibit 123: AstraZeneca PLC – Key offerings
o 12.5 Better Therapeutics Inc.
o Exhibit 124: Better Therapeutics Inc. – Overview
o Exhibit 125: Better Therapeutics Inc. – Product / Service
o Exhibit 126: Better Therapeutics Inc. – Key news
o Exhibit 127: Better Therapeutics Inc. – Key offerings
o 12.6 Boehringer Ingelheim International GmbH
o Exhibit 128: Boehringer Ingelheim International GmbH – Overview
o Exhibit 129: Boehringer Ingelheim International GmbH – Business segments
o Exhibit 130: Boehringer Ingelheim International GmbH – Key news
o Exhibit 131: Boehringer Ingelheim International GmbH – Key offerings
o Exhibit 132: Boehringer Ingelheim International GmbH – Segment focus
o 12.7 Eli Lilly and Co.
o Exhibit 133: Eli Lilly and Co. – Overview
o Exhibit 134: Eli Lilly and Co. – Product / Service
o Exhibit 135: Eli Lilly and Co. – Key news
o Exhibit 136: Eli Lilly and Co. – Key offerings
o 12.8 F. Hoffmann La Roche Ltd.
o Exhibit 137: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 138: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 139: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 140: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 141: F. Hoffmann La Roche Ltd. – Segment focus
o 12.9 GlaxoSmithKline Plc
o Exhibit 142: GlaxoSmithKline Plc – Overview
o Exhibit 143: GlaxoSmithKline Plc – Business segments
o Exhibit 144: GlaxoSmithKline Plc – Key news
o Exhibit 145: GlaxoSmithKline Plc – Key offerings
o Exhibit 146: GlaxoSmithKline Plc – Segment focus
o 12.10 Johnson and Johnson Services Inc.
o Exhibit 147: Johnson and Johnson Services Inc. – Overview
o Exhibit 148: Johnson and Johnson Services Inc. – Business segments
o Exhibit 149: Johnson and Johnson Services Inc. – Key news
o Exhibit 150: Johnson and Johnson Services Inc. – Key offerings
o Exhibit 151: Johnson and Johnson Services Inc. – Segment focus
o 12.11 Merck KGaA
o Exhibit 152: Merck KGaA – Overview
o Exhibit 153: Merck KGaA – Business segments
o Exhibit 154: Merck KGaA – Key news
o Exhibit 155: Merck KGaA – Key offerings
o Exhibit 156: Merck KGaA – Segment focus
o 12.12 Novartis AG
o Exhibit 157: Novartis AG – Overview
o Exhibit 158: Novartis AG – Business segments
o Exhibit 159: Novartis AG – Key offerings
o Exhibit 160: Novartis AG – Segment focus
o 12.13 Novo Nordisk AS
o Exhibit 161: Novo Nordisk AS – Overview
o Exhibit 162: Novo Nordisk AS – Business segments
o Exhibit 163: Novo Nordisk AS – Key offerings
o Exhibit 164: Novo Nordisk AS – Segment focus
o 12.14 Pfizer Inc.
o Exhibit 165: Pfizer Inc. – Overview
o Exhibit 166: Pfizer Inc. – Product / Service
o Exhibit 167: Pfizer Inc. – Key news
o Exhibit 168: Pfizer Inc. – Key offerings
o 12.15 Sanofi SA
o Exhibit 169: Sanofi SA – Overview
o Exhibit 170: Sanofi SA – Business segments
o Exhibit 171: Sanofi SA – Key news
o Exhibit 172: Sanofi SA – Key offerings
o Exhibit 173: Sanofi SA – Segment focus
o 12.16 Takeda Pharmaceutical Co. Ltd.
o Exhibit 174: Takeda Pharmaceutical Co. Ltd. – Overview
o Exhibit 175: Takeda Pharmaceutical Co. Ltd. – Product / Service
o Exhibit 176: Takeda Pharmaceutical Co. Ltd. – Key news
o Exhibit 177: Takeda Pharmaceutical Co. Ltd. – Key offerings
o 12.17 The Cleveland Clinic Foundation
o Exhibit 178: The Cleveland Clinic Foundation – Overview
o Exhibit 179: The Cleveland Clinic Foundation – Product / Service
o Exhibit 180: The Cleveland Clinic Foundation – Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 181: Inclusions checklist
o Exhibit 182: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 183: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 184: Research methodology
o Exhibit 185: Validation techniques employed for market sizing
o Exhibit 186: Information sources
o 13.5 List of abbreviations
o Exhibit 187: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market By Geographical Landscape
Exhibits5: Executive Summary – Chart on Market Segmentation by Type
Exhibits6: Executive Summary – Chart on Market Segmentation by Distribution Channel
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on global non-insulin diabetes therapeutics market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Type Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Distribution Channel Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Type – Market share 2022-2027 (%)
Exhibits31: Data Table on Type – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Type
Exhibits33: Data Table on Comparison by Type
Exhibits34: Chart on DPP4 inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on DPP4 inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on DPP4 inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on DPP4 inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on GLP-1 receptor agonists – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on GLP-1 receptor agonists – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on GLP-1 receptor agonists – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on GLP-1 receptor agonists – Year-over-year growth 2022-2027 (%)
Exhibits42: Chart on SGLT2 inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits43: Data Table on SGLT2 inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits44: Chart on SGLT2 inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits45: Data Table on SGLT2 inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits46: Chart on Others – Market size and forecast 2022-2027 ($ million)
Exhibits47: Data Table on Others – Market size and forecast 2022-2027 ($ million)
Exhibits48: Chart on Others – Year-over-year growth 2022-2027 (%)
Exhibits49: Data Table on Others – Year-over-year growth 2022-2027 (%)
Exhibits50: Market opportunity by Type ($ million)
Exhibits51: Data Table on Market opportunity by Type ($ million)
Exhibits52: Chart on Distribution Channel – Market share 2022-2027 (%)
Exhibits53: Data Table on Distribution Channel – Market share 2022-2027 (%)
Exhibits54: Chart on Comparison by Distribution Channel
Exhibits55: Data Table on Comparison by Distribution Channel
Exhibits56: Chart on Offline – Market size and forecast 2022-2027 ($ million)
Exhibits57: Data Table on Offline – Market size and forecast 2022-2027 ($ million)
Exhibits58: Chart on Offline – Year-over-year growth 2022-2027 (%)
Exhibits59: Data Table on Offline – Year-over-year growth 2022-2027 (%)
Exhibits60: Chart on Online – Market size and forecast 2022-2027 ($ million)
Exhibits61: Data Table on Online – Market size and forecast 2022-2027 ($ million)
Exhibits62: Chart on Online – Year-over-year growth 2022-2027 (%)
Exhibits63: Data Table on Online – Year-over-year growth 2022-2027 (%)
Exhibits64: Market opportunity by Distribution Channel ($ million)
Exhibits65: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits67: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits68: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits69: Chart on Geographic comparison
Exhibits70: Data Table on Geographic comparison
Exhibits71: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits72: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits73: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits74: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits75: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits76: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits77: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits78: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits79: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits80: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits81: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits82: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits83: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits84: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits85: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits86: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits87: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits88: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits89: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits90: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits91: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits92: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits93: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits94: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits95: Chart on China – Market size and forecast 2022-2027 ($ million)
Exhibits96: Data Table on China – Market size and forecast 2022-2027 ($ million)
Exhibits97: Chart on China – Year-over-year growth 2022-2027 (%)
Exhibits98: Data Table on China – Year-over-year growth 2022-2027 (%)
Exhibits99: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits100: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits101: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits102: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits103: Chart on India – Market size and forecast 2022-2027 ($ million)
Exhibits104: Data Table on India – Market size and forecast 2022-2027 ($ million)
Exhibits105: Chart on India – Year-over-year growth 2022-2027 (%)
Exhibits106: Data Table on India – Year-over-year growth 2022-2027 (%)
Exhibits107: Market opportunity By Geographical Landscape ($ million)
Exhibits108: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits109: Impact of drivers and challenges in 2022 and 2027
Exhibits110: Overview on Criticality of inputs and Factors of differentiation
Exhibits111: Overview on factors of disruption
Exhibits112: Impact of key risks on business
Exhibits113: Vendors covered
Exhibits114: Matrix on vendor position and classification
Exhibits115: Abbott Laboratories – Overview
Exhibits116: Abbott Laboratories – Business segments
Exhibits117: Abbott Laboratories – Key news
Exhibits118: Abbott Laboratories – Key offerings
Exhibits119: Abbott Laboratories – Segment focus
Exhibits120: AstraZeneca PLC – Overview
Exhibits121: AstraZeneca PLC – Product / Service
Exhibits122: AstraZeneca PLC – Key news
Exhibits123: AstraZeneca PLC – Key offerings
Exhibits124: Better Therapeutics Inc. – Overview
Exhibits125: Better Therapeutics Inc. – Product / Service
Exhibits126: Better Therapeutics Inc. – Key news
Exhibits127: Better Therapeutics Inc. – Key offerings
Exhibits128: Boehringer Ingelheim International GmbH – Overview
Exhibits129: Boehringer Ingelheim International GmbH – Business segments
Exhibits130: Boehringer Ingelheim International GmbH – Key news
Exhibits131: Boehringer Ingelheim International GmbH – Key offerings
Exhibits132: Boehringer Ingelheim International GmbH – Segment focus
Exhibits133: Eli Lilly and Co. – Overview
Exhibits134: Eli Lilly and Co. – Product / Service
Exhibits135: Eli Lilly and Co. – Key news
Exhibits136: Eli Lilly and Co. – Key offerings
Exhibits137: F. Hoffmann La Roche Ltd. – Overview
Exhibits138: F. Hoffmann La Roche Ltd. – Business segments
Exhibits139: F. Hoffmann La Roche Ltd. – Key news
Exhibits140: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits141: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits142: GlaxoSmithKline Plc – Overview
Exhibits143: GlaxoSmithKline Plc – Business segments
Exhibits144: GlaxoSmithKline Plc – Key news
Exhibits145: GlaxoSmithKline Plc – Key offerings
Exhibits146: GlaxoSmithKline Plc – Segment focus
Exhibits147: Johnson and Johnson Services Inc. – Overview
Exhibits148: Johnson and Johnson Services Inc. – Business segments
Exhibits149: Johnson and Johnson Services Inc. – Key news
Exhibits150: Johnson and Johnson Services Inc. – Key offerings
Exhibits151: Johnson and Johnson Services Inc. – Segment focus
Exhibits152: Merck KGaA – Overview
Exhibits153: Merck KGaA – Business segments
Exhibits154: Merck KGaA – Key news
Exhibits155: Merck KGaA – Key offerings
Exhibits156: Merck KGaA – Segment focus
Exhibits157: Novartis AG – Overview
Exhibits158: Novartis AG – Business segments
Exhibits159: Novartis AG – Key offerings
Exhibits160: Novartis AG – Segment focus
Exhibits161: Novo Nordisk AS – Overview
Exhibits162: Novo Nordisk AS – Business segments
Exhibits163: Novo Nordisk AS – Key offerings
Exhibits164: Novo Nordisk AS – Segment focus
Exhibits165: Pfizer Inc. – Overview
Exhibits166: Pfizer Inc. – Product / Service
Exhibits167: Pfizer Inc. – Key news
Exhibits168: Pfizer Inc. – Key offerings
Exhibits169: Sanofi SA – Overview
Exhibits170: Sanofi SA – Business segments
Exhibits171: Sanofi SA – Key news
Exhibits172: Sanofi SA – Key offerings
Exhibits173: Sanofi SA – Segment focus
Exhibits174: Takeda Pharmaceutical Co. Ltd. – Overview
Exhibits175: Takeda Pharmaceutical Co. Ltd. – Product / Service
Exhibits176: Takeda Pharmaceutical Co. Ltd. – Key news
Exhibits177: Takeda Pharmaceutical Co. Ltd. – Key offerings
Exhibits178: The Cleveland Clinic Foundation – Overview
Exhibits179: The Cleveland Clinic Foundation – Product / Service
Exhibits180: The Cleveland Clinic Foundation – Key offerings
Exhibits181: Inclusions checklist
Exhibits182: Exclusions checklist
Exhibits183: Currency conversion rates for US$
Exhibits184: Research methodology
Exhibits185: Validation techniques employed for market sizing
Exhibits186: Information sources
Exhibits187: List of abbreviations



★調査レポート[糖尿病用非インスリン治療薬のグローバル市場2023~2027:DPP4阻害剤、GLP-1受容体アゴニスト、SGLT2阻害剤、その他] (コード:IRTNTR70604-23)販売に関する免責事項を必ずご確認ください。
★調査レポート[糖尿病用非インスリン治療薬のグローバル市場2023~2027:DPP4阻害剤、GLP-1受容体アゴニスト、SGLT2阻害剤、その他]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆